Literature DB >> 25963305

In vitro characterisation of Span 65 niosomal formulations containing proteins.

Rita Rochdy Haj-Ahmad, Amal Ali Elkordy1, Cheng Shu Chaw.   

Abstract

Proteins can be encapsulated in niosomes as they are known to protect proteins against the surrounding environment. Niosomes of Span 65/cholesterol/pluronic F -127 were prepared by thin film hydration method. Insulin and lysozyme were chosen as model proteins. Niosomes were characterised for morphology by Transmission Electron Microscopy (TEM) and vesicles size using Dynamic Light Scattering. The entrapment efficiency of protein in niosomes was determined by complete vesicle disruption using 50:50% isopropanol:buf fer, followed by analysis of the resulting solutions by HPLC method. Thermal behaviour of the niosomes was investigated using Differential Scanning Calorimetry (DSC). Protection of proteins against simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were also assessed. The results showed that niosomes prepared with different molar ratios % of Span 65, cholesterol and pluronic F-127 successfully produced with insulin and lysozyme. For insulin containing niosomes, the ratio % of 64.7 (Span 65): 32.3 (cholesterol): 3.0 (pluronic F - 127) produced the highest protein encapsulation efficiency and the smallest vesicle size of 653.6 nm. For lysozyme containing niosomes, the maximum protein encapsulation was found in 72.75/24.25/3.00% molar ratio of Span 65/cholesterol/pluronic F -127 niosomes with vesicle size of 627.3 nm. The release study of proteins from the niosomal preparations in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) revealed that insulin and lysozyme efflux from the niosomes is a biphasic process. The results indicate that Span 65 niosomes could be developed as controlled release dosage forms for delivery of peptides and proteins such as insulin and lysozyme.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25963305     DOI: 10.2174/1567201812666150511095432

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  4 in total

1.  Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37.

Authors:  Somayeh Sadeghi; Haleh Bakhshandeh; Reza Ahangari Cohan; Afshin Peirovi; Parastoo Ehsani; Dariush Norouzian
Journal:  Int J Nanomedicine       Date:  2019-12-10

2.  The Optimized Formulation of Tamoxifen-Loaded Niosomes Efficiently Induced Apoptosis and Cell Cycle Arrest in Breast Cancer Cells.

Authors:  Iman Akbarzadeh; Mahsa Farid; Mehrnoosh Javidfar; Negar Zabet; Bahare Shokoohian; Mandana Kazem Arki; Anastasia Shpichka; Hassan Noorbazargan; Hamid Asadzadeh Aghdaei; Nikoo Hossein-Khannazer; Peter Timashev; Pooyan Makvandi; Massoud Vosough
Journal:  AAPS PharmSciTech       Date:  2022-01-19       Impact factor: 3.246

3.  Lysozyme and DNase I loaded poly (D, L lactide-co-caprolactone) nanocapsules as an oral delivery system.

Authors:  Omar S Abu Abed; Cheng Chaw; Lee Williams; Amal A Elkordy
Journal:  Sci Rep       Date:  2018-09-03       Impact factor: 4.379

4.  Formulation and Evaluation of Hybrid Niosomal In Situ Gel for Intravesical Co-Delivery of Curcumin and Gentamicin Sulfate.

Authors:  Viliana Gugleva; Victoria Michailova; Rositsa Mihaylova; Georgi Momekov; Maya Margaritova Zaharieva; Hristo Najdenski; Petar Petrov; Stanislav Rangelov; Aleksander Forys; Barbara Trzebicka; Denitsa Momekova
Journal:  Pharmaceutics       Date:  2022-03-30       Impact factor: 6.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.